An early stage clinical study shows removing a protein known as soluble Fms-like tyrosine kinase 1 (sFlt-1) from the blood of pregnant women with early stage, severe preeclampsia seems to help both mothers and babies with no significant side effects.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
